Core/surface modified nanomedicines for controlled release of drug

The current investigation presents two independent controlled drug delivering biodegradable nanomedicines that are either surface modified or surface-core modified for mitigating drug release. Particle surface modification was by coating polymeric nanoparticles with Polyelectrolytes (PEs), Poly (sodium-4-styrenesulfonate) (PSS) and Poly (allylamine hydrochloride) (PAH). Three types of nanoparticles viz poly (lactide-co-glycolic) acid [PLGA], poly(lactide-co-glycolic) acid-polyethylene imine [PLGA-PEI] and poly lactic acid [PLA] were used for this study. These nanoparticles were in the size range 80 to 150 nm. The particle size increased to 200 nm after coating with PEs. In vitro Docetaxel (DOCE) release studies demonstrated that at the end of 24 hours, about 83%, 90% and 88% of drug was released from uncoated PLA, PLGA-PEI and PLGA nanoparticles respectively. Using LbL coating, the same amount of the drug was found to be released in a sustained way for up to 7 days. Particle surface-core modification was done by encapsulating hydrophobic Superparamagnetic (SPM) nanoparticles into PLGA nanoparticle core and coating the surface with chitosan. These particles before and after coating were of size 150 nm and 300 nm respectively. Bicalutamide (BIC), a highly hydrophobic drug was found to release from this system for up to 13 days. Both the proposed approaches of drug delivery can slow down the release of drugs to a great extent. Polyelectrolytes, Magnetic nanoparticles, Sustained release.